Navigation Links
How immune cells destroy cancer cells - MDC researchers elucidate mechanism
Date:1/17/2012

In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments. The researchers showed that both forms of therapy are highly effective against large tumors. However, the T cells not only kill cancer cells they additionally destroy the tumor blood vessel system, thus impeding the supply of nutrients to the tumor. Consequently, quasi as a side effect, "escapee" mutant tumor cells are eradicated that have become resistant to drug-based treatment and are responsible for tumor recurrence. The researchers hope that their insights in defining optimal conditions for T cell therapy may help improve future clinical trials and thus the treatment of cancer patients (Cancer Cell, doi10.1016/j.ccr.2011.10.019)*.

The researchers transplanted tumor cells into mice that express SV40 large T antigen (Tag), the oncogene that is critical for tumor growth. The researchers were thus able to target and inactivate the oncogene using the antibiotic drug doxycycline (dox), which has an effect similar to modern drugs currently in clinical use. Since the oncogene is also present as antigen on the surface of the tumor cells, the researchers were also able to target these tumors with oncogene-specific T cells. Thus, for the first time the effect of the two completely different therapy approaches could be compared directly with each other.

Moreover, a special feature of the study was that the tumors in the mice were large bigger than one centimeter and containing about one billion cancer cells, comparable to clinical-size tumors in patients. Only then, according to the researchers, is the development of the tumor tissue (tumor stroma), which also includes the tumor vasculature, complete. The tumor is then considered "established". The aim of tumor therapy is to kill all cancer cells to prevent the recurrence of cancer disease.

The researchers showed in mice that the tumor is destroyed by the drug-mediated inactivation of the oncogene, but that the tumor vasculature and thus the blood supply of the tumor remains intact. In addition, due to a high mutation rate, some cancer cells become resistant to the drug and quickly generate new tumors despite continual administration of the anti-cancer drug.

Adoptive T-cell therapy, the researchers noted, is more effective in the mice in the long term, because it destroys the blood supply of the tumor. In addition, it evidently intercepts cancer cells that have altered their characteristics via mutations and thus escape drug treatment. In adoptive T-cell therapy, the researchers modulate the cytotoxic T cells (immune cells toxic for the cell) in the test tube in such a way that the T cells recognize certain features on the surface of cancer cells and specifically destroy the tumor cells. Then these primed immune cells are transferred back into the mice. The researchers point out that techniques to produce highly specialized T cells against human tumors have recently been developed following previous studies by Professor Blankenstein's research group. Now it will be important to determine exactly how these immune cells can be used in future clinical trials.

*Oncogene-targeting T cells reject large tumors, while oncogene inactivation selects escape variants in mouse models of cancer


'/>"/>
Contact: bachtler@mdc-berlin.de
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. A genetic accelerator hits the gas on autoimmune diseases
2. Gene Research Sheds Light on Rare Immune Disease
3. Self-regulation of the immune system suppresses defense against cancer
4. Severe Sepsis Can Harm the Immune System
5. Team pinpoints amino acid variation in immune response gene linked with ulcerative colitis
6. Researchers investigate link between autoimmune diseases and wounds that dont heal
7. Pep talk can revive immune cells exhausted by chronic viral infection
8. Penn researchers repair immune system in leukemia patients following chemotherapy
9. Traumatic injury sets off a genomic storm in immune system pathways
10. Autoimmune Woes May Raise Risk for Lung Clots
11. U-M Medical School and MedImmune join forces to accelerate search for new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... Orbita’s ... on Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and IoT: ... Connected Home Event hosted by Parks Associates, a market research and consulting firm ...
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., ... pen. "My wife’s hand was damaged in a firework accident, so she couldn’t grip ... with manual problems." , He then designed and created a prototype for the HELPEN ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: